Table 3.
An overview of the currently available Neisseria meningitidis vaccines.
| Vaccine | Manufacturer | Serogroups | Licensed age group | Administration schedule | Components details |
|---|---|---|---|---|---|
| AC Vax | GlaxoSmithKline, UK | A, C | 2 y+ | Single dose | 50 μg each of meningococcal polysaccharides |
|
| |||||
| ACWY Vax | GlaxoSmithKline, UK | A/C/Y/W-135 | 2 y+; can be given also at 2 mo+, even though less protective against C, Y, and W-135 | Single dose | 50 μg each of meningococcal polysaccharides |
|
| |||||
| Bexsero (4CMenB) | Novartis Vaccines and Diagnostics | B | 2 mo–17 y | Complex dose schedule depending on age: 3 doses + booster for 2–5 mo; 2 doses + booster at 6–23 mo; 2 doses at 2+ y | 50 μg of each recombinant NHBA, NadA, fHbp fusion proteins, OMVs from strain NZ98/254 containing the PorA P1.4 (25 µg), adsorbed on 0.5 mg Al3+ |
|
| |||||
| HexaMen and HexaMix | National Institute for Public Health and the Environment, Bilthoven, Netherlands | B | — | 2, 3, and 4 mo, a booster dose at 12–18 mo | OMV from two recombinant engineered strains, each of which expressed three different PorA subtypes (P1.5-2, 10; P1.12-1, 13; P1.7-2, 4; P1.19, 15-1; P1.7, 16; and P1.5-1, 2-2) |
|
| |||||
| Menactra (MenACWY-DT) | Sanofi Pasteur | A/C/Y/W-135 | 9 mo–55 y | Single dose | 4 μg each of meningococcal polysaccharides conjugated to 48 μg of a diphtheria toxoid protein carrier |
|
| |||||
| MenAfriVac (MenA-TT) | Serum Institute of India | A | 1–29 y | Single dose | 10 μg of meningococcal group A polysaccharides conjugated to 10 to 33 μg tetanus toxoid |
|
| |||||
| MenBvac | National Institute for Public Health, Norway, and Novartis | B | — | 3 doses (interval 5–12 w) | OMVs from the strain 44/76 adsorbed on Al3+ |
|
| |||||
| MencevaxA | GlaxoSmithKline and RIT, Belgium | A | 2 y+ | Single dose | 50 μg of meningococcal group A polysaccharides No conjugation |
|
| |||||
| MencevaxAC | GlaxoSmithKline | A, C | 2 y+ | Single dose | 50 μg each of meningococcal group polysaccharides No conjugation |
|
| |||||
| MencevaxACY | GlaxoSmithKline | A, C, Y | 2 y+ | Single dose | 50 μg each of meningococcal group polysaccharides No conjugation |
|
| |||||
| MencevaxACYW | GlaxoSmithKline | A/C/Y/W-135 | 2 y+ | Single dose | 50 μg each of meningococcal group polysaccharides No conjugation |
|
| |||||
| Mengivac A + C (MenPS) | Sanofi Pasteur | A, C | — | — | 50 μg of meningococcal group C polysaccharides |
|
| |||||
| MenHibrix (HibMenCY-TT) | GlaxoSmithKline | C, Y | 6 w–18 mo | 2, 4, 6, and 12 to 15 mo | Meningococcal groups C and Y polysaccharides conjugated to tetanus toxoid |
|
| |||||
| Meningitec (MenC-CRM) | Wyeth Vaccines, Canada, UK, and Australia | C | 2 mo+ | 3 doses at 2–12 mo, 1 dose at 12 mo+ | 10 μg of meningococcal group C polysaccharides conjugated to 15 μg CRM197 |
|
| |||||
| Meninvact | Sanofi Pasteur | C | 2 mo+ | 2 doses at 2–12 mo, 1 dose at 12 mo+ | Meningococcal group C polysaccharides conjugated to CRM197 |
|
| |||||
| Menitorix (Hib-MenC-TT) | GlaxoSmithKline | C | 6 w–12 mo | Booster at 1-2 y | Meningococcal group C polysaccharides conjugated to tetanus toxoid |
|
| |||||
| Menjugate (MenC-CRM) | Novartis Vaccines and Diagnostics | C | 2 mo+ | 3 doses at 2–12 mo; 1 dose at 12 mo+ | 10 μg of meningococcal group C polysaccharides conjugated to 12.5 to 25 μg CRM197 |
|
| |||||
| Menomune | Sanofi Pasteur | A, C | 2 y+ | Single dose | 50 μg each of meningococcal group polysaccharides No conjugation |
|
| |||||
| Menomune | Sanofi Pasteur | A/C/Y/W-135 | 2 y+ | Single dose | 50 μg each of meningococcal group polysaccharides No conjugation |
|
| |||||
| Menovac | Finlay Institute | A/C/Y/W-135 | 2–55 y | Single dose | Meningococcal group polysaccharides |
|
| |||||
| Menveo (MenACWY-CRM197) | Novartis Vaccines and Diagnostics | A/C/Y/W-135 | 2–55 y | Single dose | 10 μg of meningococcal group A polysaccharides and 5 μg of meningococcal groups C, Y, and W-135 polysaccharides conjugated to CRM197 |
|
| |||||
| MeNZB | Institute for Public Health, New Zealand, Chiron, Novartis | B | — | — | OMVs from strain P1.7b, 4 |
|
| |||||
| NeisVac-C (MenC-TT) | Baxter BioScience | C | 2 mo–65 y | 2 doses at 2–12 mo (with an interval of at least 2 mo), 1 dose at 12 mo+ | 10 μg of meningococcal group C polysaccharides conjugated to tetanus toxoid |
|
| |||||
| Nimenrix | GlaxoSmithKline | A/C/Y/W-135 | 1 y+ | Single dose | 5 μg each of meningococcal group polysaccharides conjugated to 44 μg tetanus toxoid |
|
| |||||
| NmVac4 | JN-International Medical Corporation | A/C/Y/W-135 | 2–55 y | Single dose | 50 μg each of meningococcal group polysaccharides |
|
| |||||
| Trumenba | Pfizer | B | 10–25 y | 3 doses (0–2–6 mo) | 120 µg of recombinant fHbp adsorbed on 0.25 mg Al3+ |
|
| |||||
| Zamevax | Imunoloski Zavod, Croatia | A, C | — | — | No conjugation |
CRM197: cross-reacting material 197; fHbp: factor H binding protein; mo: month; NadA: Neisseria adhesion A; NHBA: Neisseria heparin binding antigen, also named GNA2132; OMV: outer membrane vesicle; PorA: porin A; w: week; y: year; Al3+: Aluminum.